Ling A E, Robbins K E, Brown T M, Dunmire V, Thoe S Y, Wong S Y, Leo Y S, Teo D, Gallarda J, Phelps B, Chamberland M E, Busch M P, Folks T M, Kalish M L
1600 Clifton Rd NE, Mailstop G-19, Atlanta, GA 30333.
JAMA. 2000 Jul 12;284(2):210-4. doi: 10.1001/jama.284.2.210.
Current screening practices for blood donations have been successful in reducing human immunodeficiency virus (HIV) transmission through receipt of contaminated blood products. However, HIV-infected blood donations made prior to seroconversion and before high levels of viral replication occur could test negative using both serologic antigen and antibody tests. Testing based on nucleic acid amplification (NAT) is being implemented to screen for HIV-infected blood donated during this period, yet the issue of single vs minipool donation screening remains unresolved.
To determine HIV-1 genetic linkage between virus in 2 HIV-1-infected recipients of blood components and virus in the donor, who was HIV antigen and antibody negative at the time of donation; to screen the blood donor's plasma with HIV NAT assays, including those currently proposed for use in US blood donation screening.
Case study conducted in October 1997 involving the Communicable Disease Centre, Singapore General Hospital, and the Singapore Blood Transfusion Service, Singapore.
The blood donor and the 2 recipients of donor platelets and red blood cells.
Genetic analysis of the HIV-1 p17 coding region of gag and the C2V5 region of env to determine the genetic relatedness of virus from the donor and recipients; reactivity in quantitative and qualitative assays, and reactivity in donor screening HIV NAT assays in single donation and minipool screening contexts.
Direct DNA sequencing demonstrated identical HIV-1 subtype E viral sequences in the donor and recipients. Based on comparisons of a qualitative and quantitative assay for HIV-1 RNA levels, a low level of viremia (range, 5-39 copies/mL in plasma) was estimated to be in the donor's undiluted blood at the time of donation. Additional testing using donor-screening NAT assays showed consistent detection of HIV RNA in the undiluted donor plasma whereas detection was inconsistent at the 1:16 and 1:24 dilution levels currently used in minipool screening of blood donations in the United States.
Transmission of HIV from a blood donor to a platelet recipient and a red blood cell recipient occurred in the preseroconversion infectious window period. The viral load in the implicated donation was estimated to be less than 40 copies/mL of plasma. Current US minipool HIV NAT screening protocols may not be sufficiently sensitive to detect all infectious window-period donations. JAMA. 2000;284:210-214
目前的献血筛查方法已成功减少了因接受受污染血液制品而导致的人类免疫缺陷病毒(HIV)传播。然而,在血清转化之前且病毒尚未大量复制时所献的HIV感染血液,使用血清学抗原和抗体检测可能会呈阴性。基于核酸扩增(NAT)的检测正在用于筛查这一时期所献的HIV感染血液,但单份献血筛查与混合献血筛查的问题仍未解决。
确定2名接受血液成分的HIV-1感染者体内的病毒与献血时HIV抗原和抗体均呈阴性的献血者体内病毒之间的HIV-1基因联系;使用HIV NAT检测法对献血者的血浆进行筛查,包括目前提议用于美国献血筛查的检测法。
1997年10月在新加坡进行的一项涉及新加坡总医院传染病中心和新加坡血液输血服务中心的病例研究。
献血者以及接受献血者血小板和红细胞的2名受血者。
对HIV-1 gag基因的p17编码区和env基因的C2V5区进行基因分析,以确定献血者和受血者体内病毒的基因相关性;在定量和定性检测中的反应性,以及在单份献血和混合献血筛查情况下献血者筛查HIV NAT检测中的反应性。
直接DNA测序显示,献血者和受血者体内的HIV-1 E亚型病毒序列相同。根据对HIV-1 RNA水平的定性和定量检测比较,估计献血时献血者未稀释血液中的病毒血症水平较低(血浆中每毫升5 - 39拷贝)。使用献血者筛查NAT检测法进行的额外检测显示,在未稀释的献血者血浆中能持续检测到HIV RNA,而在美国目前用于混合献血筛查的1:16和1:24稀释水平下,检测结果不一致。
在血清转化前的感染窗口期,发生了HIV从献血者传播至血小板受血者和红细胞受血者的情况。涉事献血中的病毒载量估计低于每毫升血浆40拷贝。美国目前的混合献血HIV NAT筛查方案可能不够灵敏,无法检测出所有处于感染窗口期的献血。《美国医学会杂志》。2000年;284:210 - 214